Inhibition of mTOR by temsirolimus overcomes radio‐resistance in nasopharyngeal carcinoma. (18th May 2022)

• Record Type: Journal Article
• Authors: Huang, Shiyong; Du, Ke; Liu, Zeng; Li, Jiangping
• Is Part Of: Clinical and experimental pharmacology and physiology. Volume 49:Number 7(2022)
• Page Start: 703
• Page End: 709
• Publication Date: 2022-05-18
• Subjects: mTOR -- NPC -- radio‐resistance -- temsirolimus; Clinical pharmacology -- Periodicals; Pharmacology, Experimental -- Periodicals; Physiology, Experimental -- Periodicals; Physiology, Pathological -- Periodicals; 615.1
• DOI: 10.1111/1440-1681.13649
• Languages: English
• ISSNs: 0305-1870

Abstract

Abstract: Radio‐resistance is a leading cause of nasopharyngeal carcinoma (NPC) treatment failure and identification of sensitising therapeutic targets is an unmet need to enhance clinical management. Given that the mammalian target of rapamycin (mTOR) signalling confers resistance to cancer therapy, we investigated whether mTOR contributes to radio‐resistance in NPC and pharmacological inhibition of mTOR can overcome radio‐resistance. We found that mTOR mRNA and protein levels, and phosphorylation of its downstream effector were increased in radio‐resistant NPC compared with parental cells. mTOR inhibitor temsirolimus inhibits proliferation and induces apoptosis in a panel of NPC cell lines. Importantly, temsirolimus acts synergistically with radiation and is effective against radio‐resistant cells. Using radio‐resistant xenograft mouse model, we validated the efficacy of temsirolimus in preventing tumour formation and inhibiting tumour growth. Temsirolimus overcome radio‐resistance in NPC via inhibiting mTOR signalling. Our work provides the pre‐clinical evidence that the combination of radiation and mTOR inhibitor may be a therapeutic strategy in NPC. Our findings might accelerate the initiation of clinical trials on radio‐resistant NPC patients using temsirolimus.